10 min listen
Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer
Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer
ratings:
Length:
16 minutes
Released:
Jan 29, 2024
Format:
Podcast episode
Description
Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’Continue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Released:
Jan 29, 2024
Format:
Podcast episode
Titles in the series (100)
The Lancet Oncology: November 26, 2008 by The Lancet Oncology in conversation with